Cyclothiazide

Pricing Availability   Qty
Description: Positive allosteric modulator of AMPA receptors; inhibits AMPA desensitization
Chemical Name: 6-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiazidiazine-7-sulfonamide-1,1-dioxide
Purity: ≥98% (HPLC)
Datasheet
Citations (21)
Reviews (2)
Literature (4)

Biological Activity for Cyclothiazide

Cyclothiazide is a positive allosteric modulator of AMPA receptors that potently inhibits AMPA receptor desensitization. Selective for the flip variant of each of the four receptor subunits.

Compound Libraries for Cyclothiazide

Cyclothiazide is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.

Technical Data for Cyclothiazide

M. Wt 389.87
Formula C14H16ClN3O4S2
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 2259-96-3
PubChem ID 2910
InChI Key BOCUKUHCLICSIY-UHFFFAOYSA-N
Smiles NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Cyclothiazide

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 38.99 100
ethanol 9.75 25

Preparing Stock Solutions for Cyclothiazide

The following data is based on the product molecular weight 389.87. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.56 mL 12.82 mL 25.65 mL
5 mM 0.51 mL 2.56 mL 5.13 mL
10 mM 0.26 mL 1.28 mL 2.56 mL
50 mM 0.05 mL 0.26 mL 0.51 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for Cyclothiazide

Certificate of Analysis / Product Datasheet
Select another batch:

References for Cyclothiazide

References are publications that support the biological activity of the product.

Desai et al (1995) Cyclothiazide acts at a site on the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor complex that does not recognise competitive or noncompetitive AMPA receptor antagonists. J.Pharmacol.Exp.Ther. 272 38 PMID: 7529311

Donevan and Rogawski (1998) Allosteric regulation of a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors by thiocyanate and cyclothiazide at a common modulatory site distinct from that of 2,3-benzodiazepines. Neuroscience 87 615 PMID: 9758228

Kessler et al (2000) The norbornenyl moiety of cyclothiazide determines the preference for flip-flop variants of AMPA receptor subunits. Neurosci.Lett. 287 161 PMID: 10854736


If you know of a relevant reference for Cyclothiazide, please let us know.

View Related Products by Target

View Related Products by Product Action

View all AMPA Receptor Modulators

Keywords: Cyclothiazide, Cyclothiazide supplier, AMPA, selective, desensitization, desensitisation, inhibitors, inhibits, Glutamate, Receptors, iGluR, Ionotropic, positive, allosteric, modulators, PAM, 0713, Tocris Bioscience

21 Citations for Cyclothiazide

Citations are publications that use Tocris products. Selected citations for Cyclothiazide include:

Seebohm et al (2014) Structural basis of PI(4,5)P2-dependent regulation of GluA1 by phosphatidylinositol-5-phosphate 4-kinase, type II, alpha (PIP5K2A). Pflugers Arch 466 1885 PMID: 24389605

Bretin et al (2017) Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors. PLoS One 12 e0184429 PMID: 28886144

Falgairolle and O'Donovan (2015) Pharmacological Investigation of Fluoro-Gold Entry into Spinal Neurons. PLoS One 10 e0131430 PMID: 26102354

Maguire et al (2014) Extrasynaptic glycine receptors of rodent dorsal raphe serotonergic neurons: a sensitive target for ethanol. PLoS One 39 1232 PMID: 24264816

Menuz et al (2009) Critical role for TARPs in early development despite broad functional redundancy. Neuropharmacology 56 22 PMID: 18634809

Soto et al (2009) Selective regulation of long-form calcium-permeable AMPA receptors by an atypical TARP, gamma-5. Nat Neurosci 12 277 PMID: 19234459

Lee et al (2012) Actin-dependent rapid recruitment of reluctant synaptic vesicles into a fast-releasing vesicle pool. Proc Natl Acad Sci U S A 109 E765 PMID: 22393020

McGee et al (2015) Auxiliary Subunit GSG1L Acts to Suppress Calcium-Permeable AMPA Receptor Function. Front Cell Neurosci 35 16171 PMID: 26658868

Angelantonio et al (2015) Basal adenosine modulates the functional properties of AMPA receptors in mouse hippocampal neurons through the activation of A1R A2AR and A3R. Neuropsychopharmacology 9 409 PMID: 26528137

Harms et al (2013) Functional analysis of a novel positive allosteric modulator of AMPA receptors derived from a structure-based drug design strategy. Neuropharmacology 64 45 PMID: 22735771

Kong et al (2010) Cyclothiazide induces seizure behavior in freely moving rats. Brain Res 1355 207 PMID: 20678492

Fan et al (2018) All-optical synaptic electrophysiology probes mechanism of ketamine-induced disinhibition. Nat Methods 15 823 PMID: 30275587

Imlach et al (2016) Glycinergic dysfunction in a subpopulation of dorsal horn interneurons in a rat model of neuropathic pain Scientific Reports 6 37104 PMID: 27841371

Smejkalova and Woolley (2010) OE acutely potentiates hippocampal excitatory synaptic transmission through a presynaptic mechanism. J Neurosci 30 16137 PMID: 21123560

Oh et al (2012) Overexpression of calcium-permeable glutamate receptors in glioblastoma derived brain tumor initiating cells. PLoS One 7 e47846 PMID: 23110111

Chen et al (2013) The Munc13 proteins differentially regulate readily releasable pool dynamics and calcium-dependent recovery at a central synapse. J Neurosci 33 8336 PMID: 23658173

Kopach et al (2011) Inflammation alters trafficking of extrasynaptic AMPA receptors in tonically firing lamina II neurons of the rat spinal dorsal horn. Pain 152 912 PMID: 21282008

Bender et al (2006) Two coincidence detectors for spike timing-dependent plasticity in somatosensory cortex. J Neurosci 26 4166 PMID: 16624937

Pieri et al (2005) AMPA receptors are modulated by tachykinins in rat cerebellum neurons. J Neurophysiol 94 2484 PMID: 16160091

Takayasu et al (2006) Glial glutamate transporters maintain one-to-one relationship at the climbing fiber-Purkinje cell synapse by preventing glutamate spillover. J Neurosci 26 6563 PMID: 16775144

Bagnall et al (2008) Frequency-independent synaptic transmission supports a linear vestibular behavior. Neuron 60 343 PMID: 18957225


Do you know of a great paper that uses Cyclothiazide from Tocris? Please let us know.

Reviews for Cyclothiazide

Average Rating: 5 (Based on 2 Reviews.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Cyclothiazide?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Modulation of AMPA-receptor kinetics.
By Sergiy Sylantyev on 12/22/2020
Assay Type: In Vitro
Species: Rat
Cell Line/Tissue: Hippocampus

Cyclothiazide was used to prevent desensitization of AMPA-receptors in hippocampal pyramidal neurons. The compound prolonged the decay time of multi-synaptic evoked excitatory currents in cell somata. No difference between effects at 22-25 C and 33-36 C was detected. Illustration, grey trace: control response normalized to response amplitude under cyclothiazide.

Preparation of 10 mM ethanol stock requires sonication.

PMID: 32667048
review image

effectively blocks desensitization of AMPA receptors.
By Karthik krishnamurthy on 11/02/2018
Assay Type: In Vitro
Species: Rat
Cell Line/Tissue: motor neurons

Used to prevent desensitization AMPA receptors in motor neurons. Used at concentration of 200 micromolar to measure whole cell current in motor neurons upon AMPA application.

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.